Tiny Health offers the first at-home gut microbiome test developed for babies, using shotgun metagenomics sequencing to detect over 120,000 bacteria, fungi, viruses, archaea and parasites and deliver individualized, evidence-based recommendations. The company has expanded its suite to serve adults, children (ages 3–17), vaginal testing for expectant mothers, and a B2B platform (Powered by Tiny) for clinical and partner integrations. Tiny Health has helped more than 25,000 families and reports 25% month-over-month growth since its 2022 launch. It recently added probiotic strain-tracking capabilities to show potential colonization of probiotic strains in the gut and vaginal microbiomes. The company conducts IRB-approved clinical studies focused on maternal-infant outcomes and aims to address pediatric chronic conditions linked to early-life gut imbalances. The new funding will support platform expansion across pediatrics, women’s health, metabolic and adult chronic conditions while continuing evidence-based microbiome research and partnerships. Tiny Health is a science-based platform focused on preventing gut imbalances in babies during the critical first 1,000 days that can lead to eczema, allergies, asthma, obesity, and other chronic diseases. Its core product, the Gut Health Test, is the first to use shotgun metagenomics sequencing tailored specifically for people trying to conceive, expecting mothers, and babies aged 0–3 years. The company processes tests in a CLIA-certified lab and uses shotgun metagenomics to deliver strain-level precision and a comprehensive profile of bacteria, fungi, parasites, viruses, and archaea. Every report includes a personalized review by a team of microbiome experts and evidence-based recommendations to help parents improve their children's gut health and optimize family health. Tiny's team includes microbiologists, physicians, bioinformaticians, and entrepreneurs with backgrounds at Mayo Clinic, UCSF, Harvard Medical, Johns Hopkins, Stanford, Cornell, and WashU. The company secured $4.5M in funding.

Total raised

$13M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2024